Squarepoint
NBIX icon

Squarepoint’s Neurocrine Biosciences NBIX Stock Holding History

Squarepoint’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,300
Closed -$587K – 5134
2024
Q4 		$587K Buy
+4,300
New +$532K ﹤0.01% 3596

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's NBIX Position: Q2 2026 in Review

Squarepoint reduced its Neurocrine Biosciences (NBIX) stake by 91% in Q2 2026, selling an estimated $65.8M and leaving 44,143 shares worth $7.44M. The position accounts for 0.01% of the portfolio, ranked #1303.

Squarepoint first reported a position in NBIX in Q4 2015 and has held it in 36 quarters since. The position peaked at $64.3M in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Squarepoint held 44,143 shares of Neurocrine Biosciences worth $7.44M as of Q2 2026.
  • Squarepoint sold 443,810 Neurocrine Biosciences shares in Q2 2026, an estimated $65.8M.
  • Neurocrine Biosciences made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1303 holding.
  • Squarepoint first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 36 quarters since.
  • Squarepoint's Neurocrine Biosciences position peaked at $64.3M in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.